ÃÛÌÒ´«Ã½Æƽâ°æÏÂÔØ

The University of Colorado Connection

is pursuing a cancer treatment moonshot, developing PARN Inhibitor drugs to increase functional p53, the 'Guardian of the Genome,' to treat aggressive cancers. Dysregulation of p53, a tumor suppressor protein, is the hallmark of nearly all cancers. Drugging p53 has been considered the Holy Grail of cancer drug development. The company is the first to pursue this novel, promising therapeutic strategy of inhibiting PARN to increase functional p53 to treat wild-type p53 aggressive cancers. PARN as a target and the therapeutic strategy of inhibiting PARN to increase functional p53 was discovered by Roy Parker (ÃÛÌÒ´«Ã½Æƽâ°æÏÂÔØ Biochemistry,ÌýBioFrontiers Institute).

Funding Status and Investment Opportunities

• Industry Applications: Health and Wellness, Biotech​, Therapeutics
• Funding Round: Seed
• Contact for Investment Inquiries: , CEO, bob@IllumenTx.com

Technology Development Funding

U.S. National Institutes of Health (NIH), Howard Hughes Medical Institute

ÌýÌý ÌýThis page was last updated on April 6, 2026. Please email vpnews@colorado.edu for corrections or updates